Histone Deacetylase (HDAC) Inhibitors Market To Reach $150 Million By 2025

(MENAFN- Market Press Release) September 19, 2025 12:21 pm - The Histone Deacetylase (HDAC) Inhibitors Market is projected to reach $150 million by 2025, growing at a 7% CAGR through 2032.

Histone Deacetylase (HDAC) Inhibitors Market to Reach $150 Million by 2025, Growing at a CAGR of 7% Through 2032

The global Histone Deacetylase (HDAC) Inhibitors Market is poised for steady growth, with an estimated market size of $150 million in 2025, expanding at a CAGR of 7% from 2025 to 2032. Rising demand for targeted cancer therapies, advancements in epigenetic drug development, and increasing research activities in oncology and neurological disorders are driving market growth. North America and Europe are expected to remain key contributors, supported by strong healthcare infrastructure and robust R&D investments.

Among the major applications, oncology therapies, neurological disorder treatments, and rare disease research are driving the surge in HDAC inhibitor adoption. Oncology remains the largest segment, as these inhibitors play a crucial role in regulating gene expression and inducing apoptosis in cancer cells. Additionally, growing interest in combination therapies and clinical trials for neurodegenerative diseases is fueling demand across research institutions and pharmaceutical companies.

Price trends for HDAC inhibitors are showing moderate increases globally. In 2025, prices in the United States and Germany are projected to rise by 3–5% compared to 2024, driven by raw material costs, regulatory compliance, and enhanced formulation technologies. Japan is witnessing stable pricing due to efficient manufacturing processes and government support for innovative drugs. Overall, the market reflects a balance of increasing demand and controlled production costs.

Key players shaping the HDAC inhibitors market include F. Hoffmann-La Roche AG, Novartis AG, and Merck & Co., Inc. in North America and Europe, while Takeda Pharmaceutical Company Limited and Chugai Pharmaceutical Co., Ltd. drive innovation in Asia-Pacific. These companies are focusing on strategic partnerships, clinical trials, and pipeline expansion to strengthen their global footprint.

As HDAC inhibitors continue to demonstrate efficacy in oncology and emerging therapeutic areas, the market is expected to witness sustained growth, with increasing adoption by pharmaceutical companies, research institutes, and hospitals worldwide.

Request for customization

MENAFN20092025003520003262ID1110087946